Search

Displaying results 5261 - 5270 of 10000 in total
  1. Drug

    Rufloxacin

    go.drugbank.com/drugs/DB13772
    Investigational

    Rufloxacin is a quinolone antibiotic.[A31894]

    Categories: Topoisomerase II Inhibitors
  2. Drug

    Potassium carbonate

    go.drugbank.com/drugs/DB13977
    Approved

    Potassium carbonate (K2CO3) is a white salt, soluble in water (insoluble in ethanol) which forms a strongly alkaline solution. … It can be made as the product of potassium hydroxide's absorbent reaction with carbon dioxide. It presents a large capacity to absorb moisture.

  3. Drug

    Xaliproden

    go.drugbank.com/drugs/DB06393
    Investigational

  4. Drug

    Etiprednol dicloacetate

    go.drugbank.com/drugs/DB05442
    Investigational

    Anti-asthmatic effects were associated with decreased cytokine production in lipopolysaccharide-stimulated lymphocytes and attenuated lectin-induced proliferation of blood mononuclear cells in tissue culture … Etiprednol dicloacetate (BNP-166) is a soft corticosteroid with anti-inflammatory properties that has been indicated in the treatment of asthma and Chron's disease.

  5. Drug

    Anisodamine

    go.drugbank.com/drugs/DB11785
    Investigational

    Anisodamine has been investigated for the treatment of Intestinal Diseases.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Cyclopentamine

    go.drugbank.com/drugs/DB08999
    ApprovedWithdrawn

    Cyclopentamine is a sympathomimetic alkylamine, classified as a vasoconstrictor. Cyclopentamine was an over the counter treatment for nasal congestion in Europe and Australia. … It has been widely discontinued due to the safety, effectiveness, and availability of a similar drug, propylhexedrine.

  7. Drug

    AD 337

    go.drugbank.com/drugs/DB05725
    Investigational

    AD 337 was under investigation in clinical trial NCT00377039 (A Multicentre Trial to Determine the Efficacy and Safety of AD-337 in the Treatment of Fibromyalgia). … The drug was created by Sosei pharmaceuticals to treat Fibromyalgia in female patients.

  8. Drug

    LErafAON

    go.drugbank.com/drugs/DB04973
    Investigational

    Phase I/II trials commenced in March 2001 and were ongoing as of June 2003. … NeoPharm is developing liposome-encapsulated, c-Raf antisense oligodeoxynucleotides (LErafAON) for the potential treatment of various solid tumors, including those that have become resistant to radiation

  9. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

  10. Drug

    L523S

    go.drugbank.com/drugs/DB06498
    Investigational

    According to Nemunaitis J., et al, "L523S is an immunogenic lung cancer antigen that has demonstrated preclinical safety when the gene is injected intramuscularly as an expressive plasmid (pVAX/L523S) … [A175909] It has been investigated as a lung cancer vaccine.